10-Q: Harvard Bioscience Reports Q2 2026 Results, Revenue Up, Losses Continue

Harvard Bioscience, Inc. announced its second quarter 2026 financial results, showing an 11.1% increase in revenue to $22.7 million but a net loss of $2.9 million.

Summary

• Harvard Bioscience reported Q2 2026 revenues of $22.7 million, an 11.1% increase from $20.5 million in Q2 2025.
• The company experienced a net loss of $2.9 million for Q2 2026, compared to a net loss of $2.3 million in Q2 2025.
• For the six months ended June 30, 2026, revenues were $43.5 million, up 3.0% from $42.2 million in the prior year period.
• The net loss for the six-month period was $6.3 million, a significant improvement from $52.6 million in the prior year, which included a large goodwill impairment charge.
• The company is undergoing restructuring, including Project Viking, aimed at consolidating manufacturing operations and improving efficiency, with expected cost savings in future years.
• Cash and cash equivalents stood at $6.5 million as of June 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to continued net losses, increased interest expenses, and ongoing restructuring costs, despite revenue growth.

Positives

• Revenue increased by 11.1% to $22.7 million in Q2 2026 compared to Q2 2025.
• Revenue for the first six months of 2026 increased by 3.0% to $43.5 million compared to the same period in 2025.
• Gross profit margin improved to 57.2% for the first six months of 2026 from 56.2% in the prior year period.
• The net loss for the six-month period significantly decreased from $52.6 million in 2025 to $6.3 million in 2026, largely due to the absence of a prior year goodwill impairment charge.
• The company is implementing Project Viking to achieve estimated annual cost savings of $3 million in 2027 and $4 million annually from 2028 onwards.

Negatives

• The company reported a net loss of $2.9 million for Q2 2026, an increase from $2.3 million in Q2 2025.
• Interest expense increased significantly by 79.1% to $1.8 million in Q2 2026 compared to $1.0 million in Q2 2025, due to higher rates and amortization of financing costs.
• Gross margin slightly decreased to 55.6% in Q2 2026 from 56.4% in Q2 2025, attributed to an unfavorable product mix.
• Sales and marketing expenses increased by 19.0% in Q2 2026, driven by personnel costs, travel, and restructuring expenses.
• Restructuring costs of $0.3 million were incurred in Q2 2026 related to Project Viking.
• Cash and cash equivalents decreased to $6.5 million as of June 30, 2026, from $8.6 million as of December 31, 2025.

Risks

• The company's business is affected by global and regional economic trends and uncertainties, which could lead to customers delaying purchases.
• Increased tariffs on shipments between the United States and other countries, particularly China, could negatively affect revenue and increase costs.
• The company is involved in a potential claim for breach of contract, with an estimated range of potential loss between $0.1 million and $0.8 million.
• The company's ability to comply with covenants under the 2025 Loan Agreement, including minimum liquidity and adjusted EBITDA requirements, is a risk.
• The company's compliance with Employee Retention Tax Credit (ERTC) program qualifications may be subject to audit until May 2029.

Future Outlook

The company expects Project Viking to deliver approximately $3 million in cost savings in 2027 and approximately $4 million in annual cost savings beginning in 2028. A restructuring of sales, services, and marketing strategy is expected to deliver $1.0 to $1.2 million in cost savings in 2027 and $0.5 million in annual savings for the remainder of fiscal year 2026.

Management Comments

• The company is evolving from a traditional tools provider into a leading enabler of Translational Medicine, positioned to bridge the gap between laboratory research and human clinical success.
• Steps have been taken to rationalize the product portfolio and improve the operating cost structure, including discontinuing non-strategic products, consolidating the global operating footprint, and reducing headcount.
• The company's business has been and may continue to be negatively affected by customers forgoing or delaying purchases due to uncertainty in government funding (e.g., NIH) and by increased tariffs on international trade.

Industry Context

StockSavvy.ai notes that Harvard Bioscience operates in the life sciences tools sector, which is sensitive to R&D spending by pharmaceutical and biotech companies, as well as government funding. The company's strategy to focus on Translational Medicine aligns with industry trends towards accelerating drug development.

Comparison to Industry Standards

• The company's revenue growth of 11.1% in Q2 2026 is moderate compared to some high-growth biotech tool companies, but positive given the industry's cyclical nature.
• The net loss of $2.9 million in Q2 2026, while an improvement from the prior year's significant loss (which included a large goodwill impairment), indicates ongoing profitability challenges.
• The increased interest expense of 79.1% highlights the impact of debt financing on profitability, a common concern for companies in this sector that require significant capital investment.
• The gross margin of 55.6% is within a typical range for life science tool providers, but the slight decrease due to product mix warrants monitoring.

Legal Proceedings

• A third-party alleged a potential claim for breach of contract in January 2026; the company is defending the matter, with a potential loss estimated between $0.1 million and $0.8 million.
• The company is involved in various other claims and legal proceedings arising in the ordinary course of business, which management believes will not have a material adverse effect.

Stakeholder Impact

• Shareholders: Continued net losses and increased debt servicing costs may impact shareholder value. Revenue growth is a positive sign, but profitability remains a concern.
• Creditors: The company's compliance with debt covenants is crucial for maintaining its credit facilities.
• Employees: Restructuring efforts, including headcount reductions and facility consolidations, may impact employee morale and job security.
• Suppliers: Changes in manufacturing operations and potential cost savings initiatives could affect supplier relationships and terms.

Next Steps

• Continue implementation of Project Viking for manufacturing consolidation.
• Execute restructuring of sales, services, and marketing strategy.
• Monitor compliance with financial covenants under the 2025 Loan Agreement.
• Continue to align product portfolio, innovation pipeline, and operating model around strategic pillars for Translational Medicine.

Key Dates

Recommendation

While revenue is growing, the company continues to report net losses and faces increasing interest expenses and restructuring costs. The positive impact of cost-saving initiatives is not yet fully realized. The company's ability to achieve profitability and manage its debt load will be key factors for future performance. Therefore, a 'hold' recommendation is appropriate pending further evidence of sustained improvement.

Keywords

Harvard Bioscience, Quarterly Report, Form 10-Q, Life Sciences, Revenue Growth, Net Loss, Restructuring, Project Viking